Identification of Potent EGFR Inhibitors from TCM Database@Taiwan by Yang, Shun-Chieh et al.
Identification of Potent EGFR Inhibitors from TCM
Database@Taiwan
Shun-Chieh Yang1, Su-Sen Chang1, Hsin-Yi Chen2, Calvin Yu-Chian Chen1,2,3*
1 Laboratory of Computational and Systems Biology, School of Chinese Medicine, China Medical University, Taichung, Taiwan, 2Department of Bioinformatics, Asia
University, Taichung, Taiwan, 3China Medical University Beigang Hospital, Yunlin, Taiwan
Abstract
Overexpression of epidermal growth factor receptor (EGFR) has been associated with cancer. Targeted inhibition of the
EGFR pathway has been shown to limit proliferation of cancerous cells. Hence, we employed Traditional Chinese Medicine
Database (TCM Database@Taiwan ) (http://tcm.cmu.edu.tw) to identify potential EGFR inhibitor. Multiple Linear Regression
(MLR), Support Vector Machine (SVM), Comparative Molecular Field Analysis (CoMFA), and Comparative Molecular
Similarities Indices Analysis (CoMSIA) models were generated using a training set of EGFR ligands of known inhibitory
activities. The top four TCM candidates based on DockScore were 2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-
feruloyl tartaric acid, and all had higher binding affinities than the control IressaH. The TCM candidates had interactions with
Asp855, Lys716, and Lys728, all which are residues of the protein kinase binding site. Validated MLR (r2 = 0.7858) and SVM
(r2 = 0.8754) models predicted good bioactivity for the TCM candidates. In addition, the TCM candidates contoured well
to the 3D-Quantitative Structure-Activity Relationship (3D-QSAR) map derived from the CoMFA (q2 = 0.721, r2 = 0.986)
and CoMSIA (q2 = 0.662, r2 = 0.988) models. The steric field, hydrophobic field, and H-bond of the 3D-QSAR map were
well matched by each TCM candidate. Molecular docking indicated that all TCM candidates formed H-bonds within the
EGFR protein kinase domain. Based on the different structures, H-bonds were formed at either Asp855 or Lys716/
Lys728. The compounds remained stable throughout molecular dynamics (MD) simulation. Based on the results of this
study, 2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-feruloyl tartaric acid are suggested to be potential EGFR
inhibitors.
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Introduction
Target-specific therapies have generated much attention in
addition to conventional cancer treatments [1–3]. By targeting key
molecules essential for cellular function, replication, or tumori-
genesis, such therapies may exert cytostatic or cytotoxic effects on
tumors while minimizing nonspecific toxicities associated with
chemotherapy or irradiation [4].
The epidermal growth factor receptor (EGFR) signaling
pathway is one of the most important pathways in mammalian
cells [5]. Specific ligands, such as epidermal growth factor (EGF)
and transforming growth factor alpha (TGFa), bind and activate
EGFR, triggering autophosphorylation of the intracytoplasmic
EGFR tyrosine kinase domain [6,7]. The phosphorylated tyrosine
kinase residues serve as binding sites for signal transducers and
activators of intracellular substrates, which then stimulate
intracellular signal transduction cascades that upregulate biolog-
ical processes such as gene expression, proliferation, angiogenesis,
and inhibition of apoptosis [8]. EGFR overexpression has been
shown to activate downstream signaling pathways, resulting in
cells that have aggressive growth and invasive characteristics [9].
Tumor cell motility, adhesion, metastasis, and angiogenesis have
also been associated with stimulated EGFR pathways [10–12].
Since EGFR over-expression often differentiates tumor cells from
normal cells, it is possible for EGFR inhibitory molecules to act on
tumor cells and attenuate their proliferation rates [4].
Several tyrosine kinase inhibitors were approved for clinical use.
IressaH (gefitinib) is highly selective for EGFR tyrosine kinase and
is commonly used for treating lung cancer [13]. EGFR
downstream signaling is competitively inhibited by IressaH at its
ATP binding site [14]. Other therapeutic agents with inhibitory
mechanisms similar to IressaH include Erlotinib (TarcevaH) against
non-small cell lung cancer (NSCLC) and pancreatic cancer
[15,16], and Vandetanib (ZactimaH) against late stage medullary
thyroid cancer [17]. Lapatinib (TykerbH) is a dual inhibitor of
EGFR and HER2 tyrosine kinases approved for metastatic breast
cancer [18,19]. Though the effect of IressaH on lung cancer has
been well established, severe side effects has also been reported
[20]. Adverse reactions listed under IressaH product information
include diarrhea, skin rash and dryness, nausea, vomiting,
haemorrhage, anorexia, asthenia, and in some cases, interstitial
lung disease with fatal outcomes [21]. The adverse effects of
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available treatments necessitate continuous search efforts for
alternatives with less toxicity.
Computational predictions in biology and biomedicine are of
significant importance for generating useful data which otherwise
be time-consuming and costly through experiments alone [3,22–
27]. Computational predictions, combined with information
derived from structural bioinformatics analysis, can provide useful
insights and timely information for both basic research and drug
development [28,29]. Much cutting-edge cancer drug develop-
ment has been conducted through the use of computational
bioinformatics and modeling [30–37]. The powerful ability of
modern computational prediction and bioinformatics were
adopted in this research to search for novel EGFR inhibitors.
Traditional Chinese medicines (TCM) are natural substances
with therapeutic effects on many diseases [38–40]. The vast
number of TCM represents a rich resource that can be explored
for drug development. We had investigated kinase inhibitor
candidates from TCM targeting HER2 and HSP90 receptors
before [28,41–42]. Though EGFR kinase inhibitors have been
investigated through different screening and modeling scenarios
[43–47], none from TCM compounds has been reported to date.
This study utilized the world’s largest TCM Database@Taiwan
[48] to screen for potential EGFR inhibitors from TCM
compounds and applied structure- and ligand-based methods to
evaluate the suitability of candidates as EGFR inhibitors.
Materials and Methods
A useful predictor for a biological system should include the
following steps [49]: (i) selection of a valid dataset to train and test the
predictor; (ii) formulate samples with an effective mathematical
expression that reflects intrinsic correlation with the attribute to be
predicted; (iii) develop a powerful algorithm to operate the prediction;
(iv) objectively evaluate accuracy of the predictor through cross-
validation tests. The experimental design of the current study follows
these guidelines and details are explained in the following sections.
EGFR Protein Sequence, Structure, and Characteristics
The EGFR protein sequence (EGFR_HUMAN, P00533) used in
this study was obtained from Swiss-Prot [50], and the 3D structure
(PDB: 2ITY) [51] used for analyses was downloaded from Protein
Data Bank. The tyrosine kinase was encoded from Phe712-Leu979,
and the ATP binding site was located at Leu718–Val726.
Candidate Screening and Docking Studies
The Traditional Chinese Medicine (TCM Database@Taiwan,
url: ) database (http://tcm.cmu.edu.tw) was used to screen for
potential EGFR inhibitors from more than 20,000 compounds
within the database. All compounds were operated using the
Prepare Ligands module with Lipinski’s rule of five using
Discovery Studio 2.5 (DS 2.5; Accelrys Inc., San Diego, CA).
IressaH was selected as the control. The LigandFit program (DS
2.5) was used to locate the best docking pose for different
confirmations under the Chemistry at HARvard Macromolecular
Mechanics (CHARMm) force field [52]. Results for the docking
studies were ranked according to Dock Score.
Descriptor Generation Using Genetic Function
Approximation (GFA) Algorithm
Twenty ligands with demonstrated inhibition against EGFR
were used in this study (Table S1) [53]. Descriptors for each ligand
were identified using the Calculate Molecular Properties program
in DS 2.5. Predictive models containing five optimum descriptors
were generated using the Genetic Function Approximation (GFA)
algorithm. Descriptors in the model with the highest r2 value were
used to construct ligand activity prediction models.
Ligand Activity Predictions Using Multiple Linear
Regression (MLR) and Support Vector Machines (SVM)
A MLR model using the descriptors from the top GFA algorithm
was constructed using Matlab Statistics Toolbox (MathWorks,
Natick, MA) and validated using MLR Leave-One-Out validation
[54]. The MLR model was trained with 17 randomly selected
ligands with EGFR inhibitory activity (Table S1) and used to predict
the activity (pIC50) of the control and TCM candidates.
The identical descriptors were normalized to the range of
[21,+1] and plugged into the libSVM program to generate a
SVM prediction model[55]. Following model training with the 17-
ligand training set, the SVM model was used to predict the activity
of the control and TCM candidates.
3D Quantitative Structure-Activity Relationship (QSAR) Model
Ligands used in the previous sections were also used for 3D-
QSAR analysis. The 2-dimensional (2D) and 3-dimensional (3D)
ligand structures were drawn with ChemBioOffice 2008 (Perki-
nElmer Inc., Cambridge, MA) under a Molecular Mechanics 2
(MM2) force field. Following ligand alignment, Comparative
Molecular Field Analysis (CoMFA) and Comparative Molecular
Similarities Indices Analysis (CoMSIA) models were constructed
using partial least squares statistical method (PLS). Cross-
Validated (CV) correlation coefficient (q2) and non-cross-valida-
tion correlation coefficient (r2) were used to validate the models.
Biological activities of IressaH and TCM candidate compounds
were predicted using the generated 3D-QSAR contour map.
Molecular Dynamics Simulation
Molecular dynamics (MD) of IressaH and the TCM candidates
were simulated using DS2.5 Standard Dynamics Cascade and
Dynamics package. Sample preparation was conducted under the
following parameters: [minimization] steepest descent and conjugate
gradient: each with maximum steps of 500, [heating time] 50 ps,
[equilibration time] 200 ps. The simulations were produced with a
total production time of 20 ns with NVT, constant temperature
dynamics of Berendsen weak coupling method, a temperature decay
Author Summary
Tumor growth is associated with overexpression of
epidermal growth factors receptors. Targeted control of
EGFR by EGFR inhibitors is an attractive therapy alternative
to conventional cancer treatment that offers specificity and
reduced adverse effects. The purpose of this study was to
identify natural compounds from traditional Chinese
medicine that may be used as EGFR inhibitors. The top
four TCM compounds with the highest binding affinity to
EGFR were selected and their suitability as EGFR inhibitors
confirmed with different statistical prediction models. The
candidate compounds had higher bioactivity than IressaH,
the drug that is clinically used. The TCM compounds also
met key structural components that were characteristic
among known inhibitors. In addition, the binding between
TCM compounds and EGFR were stable which is a
fundamental requirement for any targeting drug. Results
from bioactivity prediction, structural component matching,
and binding stability all point to the possibility of these TCM
compounds as suitable EGFR inhibitor candidates.
Potent EGFR Inhibitors from TCM Database@Taiwan
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time of 0.4 ps, and a target temperature of 310K. Root mean square
deviations (RMSD) of protein-ligand complex and individual
ligands, total energy of protein-ligand complex, hydrogen bond
(H-bond), and H-bond distance were analyzed using the Analyze
Trajectory function following MD simulation.
Results/Discussion
Candidate Screening and Docking Studies
The top four TCM candidates with the highest Dock Score were
2-O-caffeoyl tartaric acid, Emitine, Rosmaricine, and 2-O-feruloyl
tartaric acid (Table 1). Corresponding scaffolds of the top TCM
candidates are illustrated in Figure 1. IressaH, Emitine, and
Rosmaricine had amine groups available for H bonding whereas
2-O-Caffeoyl tartaric acid and 2-O-feruloyl tartaric acid had
carbonyl groups. The different residues available for H bonding
resulted in different binding poses (Figure 2). Binding of IressaH
(Figure 2a), Emitine (Figure 2c), and Rosmaricine (Figure 2e) to
tyrosine kinase were located within the pocket, with H-bonds
formed between the amine group of the ligand compounds and the
carboxyl group of Asp855. 2-O-Caffeoyl tartaric acid (Figure 2b)
and 2-O-feruloyl tartaric acid (Figure 2e) docked outside the
tyrosine kinase pocket and formed multiple H-bonds through their
carboxyl groups with Lys716 and Lys728. The binding location of
2-O-caffeoyl tartaric acid and 2-O-feruloyl tartaric acid directly
blocks the ATP binding site of tyrosine kinase located from Leu718–
Val726. Dock scores of each TCM candidate is given in Table 1. All
candidates have higher dock scores than IressaH, indicating higher
binding affinities to the tyrosine kinase receptor than IressaH.
Ligand Activity Predictions Using MLR and SVM
Representative descriptors from the top GFA algorithm include:
Num_H_Acceptors_Lipinski (equivalent of N+O count), Molecu-
lar_SurfaceArea (the total surface area for each molecule using a
2D approximation), Kappa_1 (Kappa Shape Indices), PMI_Y
(principle moment of inertia Y-component), and Shadow Xlength
(length of molecule in the X dimension). The descriptors were
validated using Leave-One-Out method which is the most
objective of all available cross-validation methods [56]. The
MLR model established with the determined descriptors was:
pIC50~6:7148{0:4477 Num H Acceptors Lipinski{0:0800
Molecular SurfaceAreaz1:5172 Kappa 1z0:00027466
PMI Y{0:0452  Shadow Xlength
The SVM model was also established with the five identified
descriptors using libSVM.
Table 1. Docking score and biological activity predictions of
top TCM candidates in comparison with the control.
Predicted Activity (pIC50)
Compounds Dock Score MLR SVM
2-O-Caffeoyl tartaric acid 118.065 8.386 7.041
Emetine 113.424 5.548 7.140
Rosmaricine 105.149 4.543 7.463
2-O-Feruloyl tartaric acid 104.284 8.359 7.242
Iressa* 60.791 6.715 5.110
*control.
doi:10.1371/journal.pcbi.1002189.t001
Figure 1. Scaffolds of the control and TCM compounds. (A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, and (E) 2-O-
Feruloyl tartaric acid.
doi:10.1371/journal.pcbi.1002189.g001
Potent EGFR Inhibitors from TCM Database@Taiwan
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Correlation between the predicted and observed pIC50 activities
on EGFR ligands of known activity using the constructed MLR
and SVM models were illustrated in Figure 3a and 3b,
respectively. Correlation coefficients based on the training set
were 0.7858 for the MLR model and 0.8754 for the SVM model.
Activity predictions of IressaH and the TCM candidates using
MLR and SVM were summarized in Table 1. Both models
indicate that Iressa and the TCM candidates are compounds with
acceptable predicted activities. Predicted activities (pIC50) of Iressa
by the trained MLR and SVM models were 6.715 and 5.110,
respectively. The Iressa activity predicted by SVM was closer to
experimentally determined Iressa activities (pIC50) between 4.76–
5.96 [57], thus SVM values may be more accurate predictions of
the actual activity.
Figure 2. Docking pose of different compounds in EGFR using LigandFit. (A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D)
Rosmaricine, and (E) 2-O-Feruloyl tartaric acid. Binding site amino acids are shown in red (negatively charged amino acids) and blue (positively
charged amino acids). Hydrogen bonds are color coded based on bond distance: 1.6–1.8A˚ (orange), 1.8–2.0A˚ (yellow), 2.0–2.2A˚ (light green), 2.2–2.4A˚
(neon green), and 2.4–2.5A˚ (dark green).
doi:10.1371/journal.pcbi.1002189.g002
Potent EGFR Inhibitors from TCM Database@Taiwan
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3D QSAR Model
The results of CoMFA and CoMSIA model generation are
detailed in Table 2. Steric field was the sole factor in the CoMFA
model since the electrostatic field value was zero. Cross-validated
(q2) and non-cross-validated (r2) correlation coefficient values of
0.721 and 0.986, respectively, indicated a high level of confidence
for this model. The small standard error of estimates (SEE) and
large F-test value further supported the reliability of this model. In
contrast, CoMSIA models were influenced by multiple factors
including steric field, hydrophobic region, and hydrogen bond
donor/acceptors. Among all generated versions of the CoMSIA
model, CoMSIA_SHD had the highest r2 (0.988), lowest SEE
(0.133), and highest F value (134.272), thus was selected as the
optimum CoMSIA model for use in this study. The pIC50 of 20
ligands predicted by the constructed CoMFA and CoMSIA
models were compared with observed pIC50 reported by Fidanze
et al. [53] in Table 3. In general, both models gave similar
predicted values and were close to the experimentally determined
activities. Correlations between predicted and observed pIC50
using CoMFA and CoMSIA models are summarized in Figure 4a
and 4b, respectively. High correlation coefficients validated the
reliability of the constructed CoMFA (r2 = 0.9860) and CoM-
SIA(r2 = 0.9877) models.
Ligand activities of IressaH and the TCM candidates can be
predicted based on structural conformation to the 3D-QSAR
feature map, including features in steric field, hydrophobic field,
and H-bond donor/acceptor characteristics. As illustrated in
Figure 5, Iressa and the TCM candidates were able to match the
generated 3D-QSAR model features. The benzene in IressaH
favored steric and hydrophobic fields, and H-bond was favored
between its amine group and Asp855. In 2-O-Caffeoyl tartaric
acid, the benzene structure favored steric and hydrophobic
fields, and the carboxyl group favored H-bond formation with
Lys716 and Lys728. The carbon chain structure in Emetine
contoured to the steric and hydrophobic fields, and the amine
group favored H-bond formation with Asp855. Rosmaricine had
benzene and isopropyl structures that favored steric and
hydrophobic fields, and an amine group that favored H-bond
with Asp 855. The benzene structure in 2-O-feruloyl tartaric
acid favored steric fields and the carboxyl group favored H-bond
formations with Lys716 and Lys728. IressaH and the TCM
candidates have structural components that contour to the
features of the 3D-QSAR model, thus were likely to be
biologically active.
Figure 3. Correlation of observed and predicted activity (pIC50)
using 2D-QSAR models. (A) MLR and (B) SVM.
doi:10.1371/journal.pcbi.1002189.g003
Table 2. CoMFA and CoMSIA models as a factor of various
fractions and the corresponding validation values.
Cross
validation
Non-cross
validation Fraction
ONC q2cv r
2 SEE F S H D A
CoMFA 6 0.721 0.986 0.142 117.843 1.00 - - -
CoMFA
S 6 0.764 0.975 0.189 65.257 1.00 - - -
H 6 0.331 0.980 0.168 83.249 - 1.00 - -
D 6 0.236 0.945 0.281 28.780 - - 1.00
A 6 20.344 0.784 0.558 6.034 - - - 1.00
SH 6 0.541 0.986 0.141 118.218 0.37 0.63 - -
SD 6 0.615 0.982 0.159 92.965 0.48 - 0.52 -
SA 6 0.718 0.977 0.180 72.008 0.53 - - 0.47
HD 6 0.569 0.982 0.160 91.804 - 0.56 0.44 -
HA 6 0.265 0.979 0.176 76.040 - 0.60 - 0.40
DA 6 0.003 0.956 0.250 36.635 - - 0.60 0.40
SHD* 6 0.662 0.988 0.133 134.272 0.26 0.40 0.35 -
SHA 6 0.441 0.983 0.156 96.519 0.26 0.42 - 0.33
SDA 6 0.664 0.979 0.173 78.179 0.33 - 0.38 0.30
HDA 6 0.543 0.979 0.175 76.649 - 0.42 0.32 0.26
SHDA 6 0.665 0.985 0.148 107.106 0.20 0.31 0.27 0.22
ONC: Optimal number of components.
SEE: Standard error of estimate.
F: F-test value.
PLS: partial least squares.
S: Steric.
H: Hydrophobic.
D: Hydrogen bond donor.
A: Hydrogen bond acceptor.
*: CoMISA model selected for 3D-QSAR simulation.
doi:10.1371/journal.pcbi.1002189.t002
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Molecular Dynamics Simulation
Binding stability of the control and TCM candidates was
validated using MD simulation. RMSDs of protein-ligand complex
(Figure 6a) and individual ligand (Figure 6b) stabilized after 10 ns.
The RMSDs of the protein-ligand complexes stabilized at
approximately 1.6A˚. With regard to individual ligands, the RMSDs
of Iressa and 2-O-caffeoyl tartaric acid was 2.0 and 1.6A˚,
respectively. All other compounds registered RMSD values of
approximately 1.0A˚. The lower RMSD values of the TCM
candidates suggest more stability within the receptor compared to
Iressa. The energy trajectory of each compound is shown in
Figure 6c. Complexes formed by Rosmaricine and 2-O-feruloyl
tartaric acid had the lowest total energy (,214,800 kcal/mol),
followed by IressaH and Emetine (approximately 214,700 kcal/
mol), and 2-O-caffeoyl tartaric acid (214,600 kcal/mol). Stabiliza-
tion of total energy in ligand-protein complexes was achieved after
12 ns.
H-bond distance profiles in the EGFR receptor were
summarized in Figure 7. A single H-bond between the amine
group on IressaH and the carboxyl group on Asp855 was formed
after 9.74 ns and stabilized after 20 ns (Figure 7a). Two H-
bonds were formed between the carboxyl group of 2-O-caffeoyl
tartaric acid and Lys716 and Lys728 of the EGFR receptor
(Figure 7b). The formation of two H-bonds contributed to a
higher stability between 2-O-caffeoyl tartaric acid and the
EGFR receptor. However, an increase in H-bond distance was
observed towards the end of the 20 ns simulation period,
suggesting a weakening of the H-bond at Lys728. Emetine
formed a total of four H-bonds with the receptor, two with
Asp722 and two with Ala855 (Figure 7c). Bond distances
stabilized after 10 ns for Ala722 and 4 ns for Asp855.
Rosmaricine formed three H-bonds each at Asp841 and
Arg855 (Figure 7d). The multiple H-bonds enabled Rosmaricine
to remain in a stable state within the protein. 2-O-Feruloyl
tartaric acid also formed multiple H-bond at Lys716 and
Lys728, enhancing its stability within the receptor site
(Figure 7e). However, similar to 2-O-caffeoyl tartaric acid, an
increase in H-bond distance was also observed at Lys728 for 2-
O-feruloyl tartaric acid. These observations suggest that the
bond at Lys728 weakens throughout the MD simulation process,
and that the H-bond at Lys716 may be the primary bond for 2-
O-caffeoyl tartaric acid and 2-O-feruloyl tartaric acid. In
addition, periodic fluctuations in H-bond distances were
observed in 2-O-caffeoyl tartaric acid, Rosmaricine, and 2-O-
feruloyl tartaric acid. These phenomena can be attributed to the
rotation of the amine group where the H-bond is formed. These
Table 3. Observed and predicted activities of EGFR ligands
using the constructed CoMFA and CoMSIA models.
CoMFA CoMSIA
Comp.
Observed
pIC50
*
Predicted
pIC50 Residual
Predicted
pIC50 Residual
1 6.620 6.571 0.049 6.600 0.020
2 7.081 7.192 20.111 7.230 20.149
3 7.260 7.234 0.026 7.147 0.113
4 6.638 6.394 0.244 6.522 0.116
5 8.102 8.337 20.235 8.275 20.173
6 8.721 8.508 0.213 8.493 0.228
7 6.060 5.940 0.120 6.012 0.048
8 6.180 6.237 20.057 6.247 20.067
9 7.000 6.893 0.107 6.952 0.048
10 6.721 6.828 20.107 6.717 0.004
11 7.201 7.293 20.092 7.322 20.121
12 8.208 8.149 0.059 7.806 0.402
13 9.108 9.077 0.031 9.167 20.059
14 9.018 9.059 20.041 9.023 20.005
15 8.638 8.563 0.075 8.566 0.072
16 7.252 6.377 0.875 6.012 1.240
17 7.244 7.210 0.034 7.159 0.085
18 7.796 7.790 0.006 7.710 0.086
19 7.620 7.744 20.124 7.729 20.109
20 8.194 8.089 0.105 8.216 20.022
*: Experimental values of ligand bioactivity adapted from Ref [53].
doi:10.1371/journal.pcbi.1002189.t003
Figure 4. Correlation of observed and predicted activity (pIC50)
using 3D-QSAR models. (A) CoMFA and (B) CoMSIA.
doi:10.1371/journal.pcbi.1002189.g004
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MD results support our docking findings which identify Asp855,
Lys716, and Lys 728 as key residues for docking.
As determined in the CoMSIA model, hydrophobic interactions
were key factors contributing to ligand bioactivity. Toward the
final 20 ns of analysis, hydrophobic amino acids surrounding the
docking region were Leu718, Val726, Ala743, Cys775, Phe795,
Cys797, and Leu844. The hydrophobic subgroups of IressaH,
Emetine, and Rosmaricine were surrounded by Val726, Cys797,
and Leu844 (Figure 8a). Hydrophobic groups of 2-O-caffeoyl
tartaric acid were also surrounded Val726, Cys797, and Leu844
(Figure 8b). The hydrophobic region of 2-O-feruloyl tartaric acid
was attracted to the Phe795 on EGFR (Figure 8b). The
significance of matching the hydrophobic region of the ligand
to that of the receptor may be to increase stability of the
Figure 5. Structural contouring of different compounds to 3D-QSAR mapping. (A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine,
(D) Rosmaricine, and (E) 2-O-Feruloyl tartaric acid. 3D-QSAR features are represented by the following: steric field favor/disfavor (green/
yellow), hydrophobic field favor/disfavor (cyan/white), and hydrogen bond donor avor/disfavor (magenta/orange). Bond distances are shown
in yellow.
doi:10.1371/journal.pcbi.1002189.g005
Potent EGFR Inhibitors from TCM Database@Taiwan
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ligand-protein complex, and contribute to the bioactivity of the
activated ligand. Our results indicate that IressaH and the TCM
candidates remained stable within the EFGR hydrophobic area
following MD simulations.
Conclusion
Structural and ligand based methods supported 2-O-caffeoyl
tartaric acid, Emetine, Rosmaricine, and 2-O-feruloyl tartaric
acid as potential EGFR inhibitors. Structurally, the TCM
candidates were capable of forming H-bonds with key residues
Asp855, Lys716, and Lys728 and matched hydrophobic regions
of the receptor. Bioactivity of the candidates were evaluated
using validated MLR, SVM, CoMFA, and CoMSIA models.
All models indicated that the TCM candidates have good
predicted bioactivity. Molecular simulation results further
supported the high potential for the TCM candidates in drug
development. IressaH, the drug currently used clinically, bound
to the ERGF receptor through a single H-bond at Asp855. In
comparison, multiple H-bonds formed at Asp855 and addi-
tional H-bonds formed at Ala722 and Arg841 increase the
stability of Emetine and Rosmaricine, respectively. The ability
of carboxyl groups in 2-O-caffeoyl tartaric acid and 2-O-
feruloyl tartaric acid to form multiple H-bond networks that
directly blocked the ATP binding site was also a unique
characteristic worthwhile of further investigation. Contour to
hydrophobic regions of the TCM candidates within the
receptor site provides additional support for the stability of
the protein-ligand complex. In summary, using different
simulation and validation methods, we have identified four
TCM compounds that may have potential as novel EGFR
inhibitors. As the four TCM compounds have two distinctive
types of binding locations and bond formation within the
EGFR binding site, we suggest exploring the possibility of
connecting Emetine/Rosmaricine with 2-O-caffeoyl tartaric
acid/2-O-feruloyl tartaric acid through a spacer. The connec-
tion could allow more of points of attachment, which in turn
would contribute to more stable binding within the tyrosine
kinase site.
Figure 6. RMSD and total energy during MD simulation. (A)
Protein-ligand complex RMSD (A˚), (B) ligand RMSD (A˚) and (C) total
energy of protein-ligand complex.
doi:10.1371/journal.pcbi.1002189.g006
Figure 7. Hydrogen bond distance profile during MD simulation. (A) Iressa, (B) 2-O-Caffeoyl tartaric acid, (C) Emetine, (D) Rosmaricine, (E) 2-
O-Feruloyl tartaric acid.
doi:10.1371/journal.pcbi.1002189.g007
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Supporting Information
Table S1 Molecular structures and biological activities
of ligands used for model training. Structural details of the
20 ligands adopted for ligand-based studies are listed within this
table. Experimental bioactivity values for each ligand were
adapted from Ref [53].
(DOC)
Acknowledgments
We are grateful to the Asia University cloud-computing facilities.
Author Contributions
Conceived and designed the experiments: CYCC. Performed the
experiments: SCY HYC CYCC. Analyzed the data: SCY SSC.
Contributed reagents/materials/analysis tools: HYC CYCC. Wrote the
paper: SCY SSC CYCC.
References
1. de Oliveira AN, Bocca CC, Carvalho JE, Ruiz AL, Silva TP, et al. (2010) New
substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell
lines: in vitro and docking experiments. Eur J Med Chem 45: 4339–4342.
2. El-Azab AS, Al-Omar MA, Abdel-Aziz AA, Abdel-Aziz NI, el-Sayed MA, et al.
(2010) Design, synthesis and biological evaluation of novel quinazoline
derivatives as potential antitumor agents: molecular docking study. Eur J Med
Chem 45: 4188–4198.
3. Wang P, Hu L, Liu G, Jiang N, Chen X, et al. (2011) Prediction of antimicrobial
peptides based on sequence alignment and feature selection methods. PLoS One
6: e18476.
4. Herbst RS (2004) Review of epidermal growth factor receptor biology.
Int J Radiat Oncol Biol Phys 59: 21–26.
5. Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway
map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 1–17.
6. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA, Jr. (2002) Epidermal
growth factor receptor family in lung cancer and premalignancy. Semin Oncol
29: 3–14.
7. Linggi B, Carpenter G (2006) ErbB receptors: new insights on mechanisms and
biology. Trends Cell Biol 16: 649–656.
8. Chan TO, Rittenhouse SE, Tsichlis PN (1999) AKT/PKB and other D3
phosphoinositide-regulated kinases: kinase activation by phosphoinositide-
dependent phosphorylation. Ann Rev Biochem 68: 965–1014.
9. Either SP (2002) Signal transduction pathways: the molecular basis for targeted
therapies. Semin Radiat Oncol 12: 3–10.
10. Shibata T, Kawano T, Nagayasu H, Okumura K, Arisue M, et al. (1996)
Enhancing effects of epidermal growth factor on human squamous cell
carcinoma motility and matrix degradation but not growth. Tumour Biol 17:
168–175.
11. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, et al. (1997) Neutralizing
antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine
kinases down-regulate vascular endothelial growth factor production by tumor
cells in vitro and in vivo: angiogenic implications for signal transduction therapy
of solid tumors. Am J Pathol 151: 1523–1530.
12. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to
tumor development: EGFR gene and cancer. FEBS J: 277: 301–308.
13. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways. Science 305:
1163–1167.
14. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, et al. (1996)
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-
anilinoquinazolines. Breast Cancer Res Treat 38: 67–73.
15. Merlo V, Longo M, Novello S, Scagliotti GV (2011) EGFR pathway in
advanced non-small cell lung cancer. Front Biosci 3: 501–517.
16. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP (2011) Epidermal growth
factor receptor targeted therapies for solid tumours. Acta Clin Belg 66: 10–17.
17. Sherman SI (2011) Targeted therapies for thyroid tumors. Mod Pathol 24:
S44–52.
18. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal
growth factor receptor tyrosine kinases. Clin Ther 30: 1426–1447.
19. Johnston SR, Leary A (2006) Lapatinib: a novel EGFR/HER2 tyrosine kinase
inhibitor for cancer. Drugs Today (Barc) 42: 441–453.
20. Forsythe B, Faulkner K (2004) Overview of the tolerability of gefitinib (IRESSA)
monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 27:
1081–1092.
21. AustraZeneca Pharmaceuticals (2011) Iressa Product Information. Available:
http://www.iressa.com/product-information. Accessed 15 May 2011.
22. Chen L, Huang T, Shi XH, Cai YD, Chou KC (2010) Analysis of protein
pathway networks using hybrid properties. Molecules 15: 8177–8192.
23. Huang T, Shi XH, Wang P, He Z, Feng KY, et al. (2010) Analysis and
prediction of the metabolic stability of proteins based on their sequential
features, subcellular locations and interaction networks. PLoS One 5:
e10972.
Figure 8. Hydrophobic interactions of different compounds in EGFR. (A) Iressa (orange), Emetine (green), and Rosmaricine (violet) (B) 2-O-
Caffeoyl tartaric acid (blue), and 2-O-feruloyl tartaric acid (green). The hydrophobic regions in the binding site are depicted in red, and specific
hydrophobic amino acids close to TCM compounds are indicated in red.
doi:10.1371/journal.pcbi.1002189.g008
Potent EGFR Inhibitors from TCM Database@Taiwan
PLoS Computational Biology | www.ploscompbiol.org 9 October 2011 | Volume 7 | Issue 10 | e1002189
24. Chou KC (1996) Review: Prediction of HIV protease cleavage sites in proteins.
Anal Biochem 233: 1–14.
25. Chou KC (2001) Prediction of protein cellular attributes using pseudo-amino
acid composition. Proteins 43: 246–255.
26. Shen HB, Chou KC (2008) HIVcleave: a web-server for predicting HIV
protease cleavage sites in proteins. Anal Biochem 375: 388–390.
27. Chou KC, Wu ZC, Xiao X (2011) iLoc-Euk: A multi-label classifier for
predicting the subcellular localization of singleplex and multiplex eukaryotic
proteins. PLoS One 6: e18258.
28. Chou KC (2004) Structural bioinformatics and its impact to biomedical science.
Curr Med Chem 11: 2105–2134.
29. Chou KC, Shen HB (2009) Review: Recent advances in developing web-servers
for predicting protein attributes. Nat Sci 2: 63–92.
30. Liao QH, Gao QZ, Wei J, Chou KC (2011) Docking and molecular dynamics
study on the inhibitory activity of novel inhibitors on epidermal growth factor
receptor (EGFR). Med Chem 7: 24–31.
31. Mustafa M, Mirza A, Kannan N (2011) Conformational regulation of the EGFR
kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics
study. Proteins 79: 99–114.
32. Krug M, Wichapong K, Erlenkamp G, Sippl W, Schachtele C, et al. (2011)
Discovery of 4-benzylamino-substituted alpha-carbolines as a novel class of
receptor tyrosine kinase inhibitors. ChemMedChem 6: 63–72.
33. Zheng Y, Wu X, Xue B, Li M, Ji M (2010) Design, synthesis, docking and
antitumor activity of quinazolino [3, 4-a] thieno [3, 2-d] pyrimidin-8-one
derivatives. Chem Biol Drug Des 76: 285–290.
34. Qian Y, Zhang HJ, Zhang H, Xu C, Zhao J, et al. (2010) Synthesis, molecular
modeling, and biological evaluation of cinnamic acid metronidazole ester
derivatives as novel anticancer agents. Bioorg Med Chem 18: 4991–4996.
35. Lv PC, Li HQ, Sun J, Zhou Y, Zhu HL (2010) Synthesis and biological
evaluation of pyrazole derivatives containing thiourea skeleton as anticancer
agents. Bioorg Med Chem 18: 4606–4614.
36. Ali HI, Nagamatsu T, Akaho E (2011) Structure-based drug design and
AutoDock study of potential protein tyrosine kinase inhibitors. Bioinformation 5:
368–374.
37. Nandi S, Bagchi MC (2010) 3D-QSAR and molecular docking studies of 4-
anilinoquinazoline derivatives: a rational approach to anticancer drug design.
Mol Divers 14: 27–38.
38. Cheng WY, Wu SL, Hsiang CY, Li CC, Lai TY, et al. (2008) Relationship
between San-Huang-Xie-Xin-Tang and its herbal components on the gene
expression profiles in HepG2 cells. Am J Chin Med 36: 783–797.
39. Liu SH, Liu YF, Liou SH, Lin YL, Hsiao YC, et al. (2010) Mortality and cancer
incidence among physicians of traditional Chinese medicine: a 20-year national
follow-up study. Occup Environ Med 67: 166–169.
40. Hsu CH, Yu MC, Lee CH, Lee TC, Yang SY (2003) High eosinophil cationic
protein level in asthmatic patients with "heat" Zheng. Am J Chin Med 31:
277–283.
41. Huang HJ, Lee KJ, Yu HW, Chen CY, Hsu CH, et al. (2010) Structure-based
and ligand-based drug design for HER2 receptor. J Biomol Struct Dyn 28:
23–37.
42. Chen CY, Chen CYC (2010) Insights into designing the dual-targeted HER2/
HSP90 inhibitors. J Mol Graph Model 29: 21–31.
43. Choowongkomon K, Sawatdichaikul O, Songtawee N, Limtrakul J (2010)
Receptor-based virtual screening of EGFR kinase inhibitors from the NCI
diversity database. Molecules 15: 4041–4054.
44. Abou-Seri SM (2010) Synthesis and biological evaluation of novel 2,49-bis
substituted diphenylamines as anticancer agents and potential epidermal growth
factor receptor tyrosine kinase inhibitors. Eur J Med Chem 45: 4113–4121.
45. Pasha FA, Muddassar M, Srivastava AK, Cho SJ (2010) In silico QSAR studies
of anilinoquinolines as EGFR inhibitors. J Mol Model 16: 263–277.
46. Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, et al. (2010) Fast-forwarding
hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead
identification. J Med Chem 53: 4980–4988.
47. Konkimalla VB, Efferth T (2010) Inhibition of epidermal growth factor receptor-
overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.
Biochem Pharmacol 80: 39–49.
48. Chen CYC (2011) TCM Database@Taiwan: the world’s largest traditional
Chinese medicine database for drug screening in silico. PLoS One 6: e15939.
49. Chou KC (2011) Some remarks on protein attribute prediction and pseudo
amino acid composition. J Theor Biol 273: 236–247.
50. The UniProt Consortium (2010) Ongoing and future developments at the
Universal Protein Resource. Nucleic Acids Res 39: D214–D219.
51. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung
cancer-derived EGFR mutants and inhibitor complexes: mechanism of
activation and insights into differential inhibitor sensitivity. Cancer Cell 11:
217–227.
52. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, et al. (2009)
CHARMM: the biomolecular simulation program. J Comput Chem 30:
1545–1614.
53. Fidanze SD, Erickson SA, Wang GT, Mantei R, Clark RF, et al. (2010)
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth
factor receptor and members of the epidermal growth factor family of receptor
tyrosine kinases. Bioorg Med Chem Lett 20: 2452–2455.
54. Picard RR, Cook RD (1984) Cross-validation of regression models. J Am Stat
Assoc 79: 575–583.
55. Fan RE, Chen PH, Lin CJ (2005) Working set selection using second order
information for training support vector machines. J Mach Learn Res 6:
1889–1918.
56. Chou KC, Shen HB (2007) Review: Recent progresses in protein subcellular
location prediction. Anal Biochem 370: 1–16.
57. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, et al. (2009) Proteomic
Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways
Correspond to Gefitinib Sensitivity in Head and Neck Cancer. Clin Cancer Res
15: 2361–2372.
Potent EGFR Inhibitors from TCM Database@Taiwan
PLoS Computational Biology | www.ploscompbiol.org 10 October 2011 | Volume 7 | Issue 10 | e1002189
